Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học General Psychiatry cung cấp cho các bạn kiến thức về ngành y đề tài: Recent developments in anti-rheumatic drugs in pediatrics: treatment of juvenile idiopathic arthritis. | Available online http content 11 1 216 Review Recent developments in anti-rheumatic drugs in pediatrics treatment of juvenile idiopathic arthritis Kristen Hayward and Carol A Wallace Division of Rheumatology University of Washington School of Medicine Seattle Children s Hospital 4800 Sandpoint Way NE MS R-5420 Seattle WA 98105 USA Corresponding author Carol A Wallace cwallace@ Published 23 February 2009 Arthritis Research Therapy 2009 11 216 doi ar2619 This article is online at http content 11 1 216 2009 BioMed Central Ltd Abstract Juvenile idiopathic arthritis JIA is the most common autoimmune-autoinflammatory disease in childhood and affects approximately 1 in 1 000 children. Despite advances in diagnosis and treatment options JIA remains a chronic condition for most affected children. Recent evidence suggests that disease control at onset may determine the tempo of subsequent disease course and long-term outcomes and raises the concept of a therapeutic window of opportunity in patients with JIA. This underscores the importance of early aggressive treatment in patients with JIA. With the advent of novel biologic therapeutics the repertoire of agents available for treatment of children with JIA has greatly increased. The present article will summarize recent developments in the medical treatment of children with JIA and will offer insights into emerging therapies. Introduction Juvenile idiopathic arthritis JIA is a chronic autoimmune-autoinflammatory disease of unknown etiology. It is estimated that JIA affects up to 1 in 1 000 children worldwide and is the most common cause of autoimmune musculoskeletal disease in children 1 . By definition children with JIA have disease onset prior to age 16 years and present with joint pain stiffness and swelling that persists for longer than 6 weeks. Formerly referred to as juvenile rheumatoid arthritis the classification scheme for JIA was updated by the .
